Reports Q4 revenue $304.7M, consensus $289.8M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALKS:
- Alkermes: Nemvaleukin alfa granted an Innovation Passport by MHRA
- Alkermes price target raised to $28 from $27 at BofA
- Alkermes reports interim award in arbitration proceedings with Janssen
- Piper recommends ‘down market cap’ biotech exposure for 2023
- Alkermes positioned for ‘considerable value creation,’ says Piper Sandler